<DOC>
	<DOCNO>NCT01136772</DOCNO>
	<brief_summary>The purpose research study compare `` real-world '' effectiveness two FDA-approved widely use long-acting injectable antipsychotic medication ( paliperidone palmitate haloperidol decanoate ) patient schizophrenia schizoaffective disorder expect benefit improved medication compliance associate injectable medication . The goal evaluate effect medication outcome importance patient ( relapse , symptom , adverse effect , function ) well policy maker ( plus cost ) .</brief_summary>
	<brief_title>A Comparison Long-acting Injectable Medications Schizophrenia</brief_title>
	<detailed_description>The purpose comparative effectiveness research study learn different medication call antipsychotic use treat schizophrenia schizoaffective disorder . Specifically , look long-acting medication give injection every month , instead take mouth every day . In multi-site study , compare risk benefit two FDA-approved long-acting injectable medication ( paliperidone palmitate haloperidol decanoate ) . Study participant schizophrenia schizoaffective disorder expect benefit improved medication schedule . This study aim enroll 360 individual schizophrenia schizoaffective disorder treatment long-acting injectable antipsychotic medication likely helpful . Study participant randomly assign treatment either paliperidone palmitate haloperidol decanoate 24 month . Participants equal chance assign medication , however participant know medication taking .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Decanoic acid</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder define DSMIVTR criterion Age 1865 year Capacity provide informed consent Patients likely benefit treatment longacting injectable paliperidone palmitate haloperidol decanoate Women child bear potential must negative serum pregnancy test Screening Visit . Patients currently stable well antipsychotic regimen Patients expect benefit study medication due past experience risperidone , paliperidone haloperidol Patients tardive dyskinesia moderate severe Patients medical condition , judgment investigator , might preclude safe completion study Women pregnant breastfeeding Patients mental retardation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>